(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has launched its “Alnylam 5x15” product strategy focused on the development of innovative RNAi therapeutics for genetically defined diseases addressing major unmet medical needs. The company expects to progress five RNAi therapeutic programs into advanced clinical development by 2015, with the potential for early commercialization opportunities. Alnylam also announced additional product and business goals for 2011 and increased its guidance for its 2010 year-end cash position.
